The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2025 |
Bahadır Köylü, Cenk Sökmensüer, Muşturay Karçaaltıncaba, Onur Keskin. Predicting Fibrosis Stage in MASH: The Role of Total Metabolic Syndrome Score and MMP-1, Medicina. 2025; 61: 1102. https://doi.org/10.3390/medicina61061102 |
|
2 |
2025 |
Oscar R. Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge I. Castañeda-Sánchez, Elena Aréchaga-Ocampo, Estefanía Valle-Velázquez, Juan C. Cabrera-Angeles, José L. Sánchez-Gloria, Fausto Sánchez-Muñoz, Abraham S. Arellano-Buendia, Laura G. Sánchez-Lozada, Horacio Osorio-Alonso. Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors, Life Sciences. 2025; 372: 123638123638. https://doi.org/10.1016/j.lfs.2025.123638 |
|
3 |
2025 |
Khushi Dahiya, Mahesh Palkar, Sanjay Sharma. Unlocking the potential of THR-β agonist therapies: resmetirom’s chemistry, biology, and patent insights, Naunyn-Schmiedeberg's Archives of Pharmacology. 2025; 398: 9703. https://doi.org/10.1007/s00210-025-03880-y |
|
4 |
2025 |
Mohammad Aabis, Priyanka Tiwari, Vinod Kumar, Gurpreet Singh, Archana Panghal, Gopabandhu Jena. Pentadecanoic acid attenuates thioacetamide-induced liver fibrosis by modulating oxidative stress, inflammation, and ferroptosis pathways in rat, Naunyn-Schmiedeberg's Archives of Pharmacology. 2025; https://doi.org/10.1007/s00210-025-04143-6 |